Janssen-Cilag International NV , today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or ... (more)
http://www.biospace.com/news_story.aspx?StoryID=311806&full=1
http://www.biospace.com/news_story.aspx?StoryID=311806&full=1
No comments:
Post a Comment